Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

RHPN1-AS1 Drives the Progression of Hepatocellular Carcinoma via Regulating miR-596/IGF2BP2 Axis

Author(s): Hu Fen, Zheng Hongmin, Wei Wei, Yang Chao, Yao Yang, Liu Bei and Sun Zhihua*

Volume 25, Issue 43, 2019

Page: [4630 - 4640] Pages: 11

DOI: 10.2174/1381612825666191105104549

open access plus

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most deadly cancer types worldwide, and its incidence is high in China. Multiple long non-coding RNAs (lncRNAs) have been recently identified as crucial oncogenic factors or tumor suppressors. In this study, we explored the effects of LncRNA RHPN1 antisense RNA 1 (RHPN1-AS1) on the progression of HCC.

Methods: Expression levels of RHPN1-AS1 and miR-596 in HCC samples were measured by qRT-PCR. The association between pathological indexes and the expression level of RHPN1-AS1 was also analyzed. Human HCC cell lines Huh7 and SMMC-7721 were used as cell models. CCK-8 and colony formation assays were performed to assess the effect of RHPN1-AS1 on HCC cell line proliferation. The flow cytometer instrument was used to study the effect of RHPN1-AS1 on apoptosis of HCC cells. The transwell assay was conducted to detect the effect of RHPN1-AS1 on migration and invasion. Furthermore, luciferase reporter assay was used to confirm targeting of miR-596 by RHPN1-AS1. Additionally, the regulatory function of RHPN1-AS1 on insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) was detected by western blot.

Results: The expression level of RHPN1-AS1 in HCC samples was observed to significantly increase compared with normal tissues and its high expression was correlated with unfavorable pathological indexes. Highly expressed RHPN1-AS1 was associated with shorter overall survival time. RHPN1-AS1 overexpression remarkably accelerated proliferation and metastasis of HCC cells, while reduced apoptosis. Accordingly, RHPN1-AS1 knockdown suppressed the malignant phenotypes of HCC cells. RHPN1-AS1 overexpression significantly reduced miR-596 expression by sponging it, but enhanced IGF2BP2 expression.

Conclusion: RHPN1-AS1 acts as a sponge of tumor suppressor miR-596 in HCC that can indirectly enhance the IGF2BP2 expression and function as an oncogenic lncRNA.

Keywords: RHPN1-AS1, miR-596, IGF2BP2, HCC, oncogenic lncRNA, CCK-8.

« Previous
[1]
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 16-27.
[http://dx.doi.org/10.1158/1055-9965.EPI-15-0578] [PMID: 26667886]
[2]
Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis 2015; 19(1): 23-43.
[http://dx.doi.org/10.1016/j.cld.2014.09.002] [PMID: 25454295]
[3]
Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res 2016; 5 pii: F1000 Faculty Rev-879
[4]
Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer 2016; 139(2): 269-80.
[http://dx.doi.org/10.1002/ijc.30039] [PMID: 26875870]
[5]
Jang SY, Kim G, Park SY, et al. Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. Oncotarget 2017; 8(45): 78588-97.
[http://dx.doi.org/10.18632/oncotarget.21094] [PMID: 29108251]
[6]
Luo P, Jing W, Zhu M, et al. Decreased expression of LncRNA SRA1 in hepatocellular carcinoma and its clinical significance. Cancer Biomark 2017; 18(3): 285-90.
[http://dx.doi.org/10.3233/CBM-160305] [PMID: 28085012]
[7]
Li X, Zhang X, Yang C, Cui S, Shen Q, Xu S. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell Cycle 2018; 17(14): 1772-83.
[http://dx.doi.org/10.1080/15384101.2018.1496745] [PMID: 30010468]
[8]
Lu L, Yu X, Zhang L, et al. The Long Non-Coding RNA RHPN1-AS1 promotes uveal melanoma progression. Int J Mol Sci 2017; 18(1) E226
[http://dx.doi.org/10.3390/ijms18010226] [PMID: 28124977]
[9]
Zhu P, Li Y, Li P, Zhang Y, Wang X. c-Myc induced the regulation of long non-coding RNA RHPN1-AS1 on breast cancer cell proliferation via inhibiting P53. Mol Genet Genomics 2019; 294(5): 1219-29.
[http://dx.doi.org/10.1007/s00438-019-01572-w] [PMID: 31089812]
[10]
Sartorius K, Sartorius B, Winkler C, Chuturgoon A, Makarova J. The biological and diagnostic role of miRNA’s in hepatocellular carcinoma. Front Biosci 2018; 23: 1701-20.
[http://dx.doi.org/10.2741/4668] [PMID: 29293458]
[11]
Hu Z, Wang P, Lin J, et al. MicroRNA-197 promotes metastasis of hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cell Physiol Biochem 2018; 51(1): 470-86.
[http://dx.doi.org/10.1159/000495242] [PMID: 30453289]
[12]
Liu Q, Xu Y, Wei S, et al. miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. Biosci Rep 2015; 35(4) e00229
[http://dx.doi.org/10.1042/BSR20150084] [PMID: 25997710]
[13]
Liu SM, Lin CH, Lu J, et al. miR-596 modulates melanoma growth by regulating cell survival and death. J Invest Dermatol 2018; 138(4): 911-21.
[http://dx.doi.org/10.1016/j.jid.2017.11.016] [PMID: 29183729]
[14]
Zhang Z, Dai DQ. MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation. World J Gastroenterol 2019; 25(10): 1224-37.
[http://dx.doi.org/10.3748/wjg.v25.i10.1224] [PMID: 30886505]
[15]
Wei M, Cao Y, Jia D, Zhao H, Zhang L. CREPT promotes glioma cell proliferation and invasion by activating Wnt/β-catenin pathway and is a novel target of microRNA-596. Biochimie 2019; 162: 116-24.
[http://dx.doi.org/10.1016/j.biochi.2019.04.014] [PMID: 30995540]
[16]
Wachter DL, Kristiansen G, Soll C, et al. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology 2012; 60(2): 278-86.
[http://dx.doi.org/10.1111/j.1365-2559.2011.04091.x] [PMID: 22211286]
[17]
Kessler SM, Laggai S, Barghash A, et al. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis 2015; 6 e1894
[http://dx.doi.org/10.1038/cddis.2015.241] [PMID: 26426686]
[18]
Isin M, Dalay N. LncRNAs and neoplasia. Clin Chim Acta 2015; 444: 280-8.
[http://dx.doi.org/10.1016/j.cca.2015.02.046] [PMID: 25748036]
[19]
Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014; 25(5): 666-81.
[http://dx.doi.org/10.1016/j.ccr.2014.03.010] [PMID: 24768205]
[20]
Xie X, Wang X, Liao W, et al. MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development. J Exp Clin Cancer Res 2018; 37(1): 28.
[http://dx.doi.org/10.1186/s13046-018-0693-7] [PMID: 29439719]
[21]
Yu Q, Xiang L, Yin L, Liu X, Yang D, Zhou J. Loss-of-function of miR-142 by hypermethylation promotes TGF-β-mediated tumour growth and metastasis in hepatocellular carcinoma. Cell Prolif 2017; 50(6)
[http://dx.doi.org/10.1111/cpr.12384] [PMID: 28963738]
[22]
Xue H, Tian GY. MiR-429 regulates the metastasis and EMT of HCC cells through targeting RAB23. Arch Biochem Biophys 2018; 637: 48-55.
[http://dx.doi.org/10.1016/j.abb.2017.11.011] [PMID: 29191386]
[23]
Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics 2017; 15(3): 177-86.
[http://dx.doi.org/10.1016/j.gpb.2016.12.005] [PMID: 28529100]
[24]
Ma M, Yang J, Wang B, Zhao Z, Xi JJ. High-throughput identification of miR-596 inducing p53-mediated apoptosis in HeLa and HCT116 cells using cell microarray. SLAS Technol 2017; 22(6): 636-45.
[http://dx.doi.org/10.1177/2472630317720870] [PMID: 28732184]
[25]
Simon Y, Kessler SM, Bohle RM, Haybaeck J, Kiemer AK. The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut 2014; 63(5): 861-3.
[http://dx.doi.org/10.1136/gutjnl-2013-305736] [PMID: 24173291]
[26]
Tai BJ, Yao M, Zheng WJ, et al. Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation. HBPD INT 2019; 18(2): 158-63.
[http://dx.doi.org/10.1016/j.hbpd.2019.01.003] [PMID: 30692043]
[27]
Liu FY, Zhou SJ, Deng YL, et al. MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis 2015; 6 e1670
[http://dx.doi.org/10.1038/cddis.2015.46] [PMID: 25741595]

Rights & Permissions Print Cite
Article Metrics
27
4
© 2024 Bentham Science Publishers | Privacy Policy